Redirecting T cells to treat solid pediatric cancers

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Immune checkpoint inhibitors show promise in solid tumors by activating T cells.
• Chimeric receptor engineered T cells demonstrate efficacy in B-lineage malignancies.
• Childhood cancers often lack pre-existing T cell responses, necessitating alternative therapeutic approaches.

Purpose of the Study:

• To review strategies for engineering T cells to recognize specific tumor antigens.
• To highlight candidate target antigens for pediatric malignancies in preclinical and clinical trials.
• To discuss limitations and innovative solutions for redirected T cell therapy in solid tumors.

Main Methods:

• Review of current literature on T cell modification and engineering.
• Focus on chimeric receptor engineering strategies.
• Analysis of preclinical and clinical trial data for pediatric malignancies.

Main Results:

• T cell engineering offers a method to redirect T cells against cancers lacking endogenous antitumor responses.
• Several candidate target antigens are under investigation for pediatric solid tumors.
• Challenges include T cell function in the tumor microenvironment and antigen heterogeneity.

Conclusions:

• Engineered T cell therapy, particularly chimeric receptor T cells, holds significant potential for treating pediatric cancers.
• Overcoming limitations in T cell recruitment, antigen targeting, and microenvironment resistance is crucial for therapeutic success.
• Innovative strategies are needed to enhance the efficacy and broaden the application of T cell-based cancer immunotherapies.